EUCTR2019-000256-33-SE进行中（未招募）1 期
A randomized, double-blinded, placebo-controlled study of Rituximab in patients with Psychosis and/or Obsessive Compulsive Disorder, with an indication of immune system involvement
ppsala University Hospital0 个研究点目标入组 40 人开始时间: 2019年5月14日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •General criteria
- •1.Diagnostic criteria: ICD 10 at least one of the following ICD 10 diagnoses:
- •a.Obsessive-compulsive disorder ICD F42 or
- •b.Obsessive-compulsive behavior ICD R46.81 AND/OR
- •c.Schizophrenia, delusional, and other non-mood psychotic disorders, namely
- •?F20 Schizophrenia
- •?F22 Delusional disorders
- •?F23 Brief psychotic disorder
- •?F25 Schizoaffective disorders
- •?F28 Other psychotic disorder not due to a substance or known physiological condition
- •?F29 Unspecified psychosis not due to a substance or known physiological condition
- •2.Age: 18-55
- •3.Severity: Clinical Global impression (CGI): Minimum score of 4 = Moderately ill”
- •4.Swedish or English proficiency
- •5.The patient has tried at least 2 standard psychiatric medications at maximal tolerable or maximal recommended dosage for his/her current condition over a period of 6 months, but has not improved significantly
- •6.Medication has been unchanged for at least one month prior to study start
- •7.Signed informed consent
- •8.Use of adequate contraception
- •9.Radiological evidence of brain atrophy and scarring are absent
- •10.The clinical picture indicates active inflammatory activity (see specific criteria below), potential for rehabilitation and time from disease and/or episode debut is no longer than 10 years.
- •Specific criteria
- •11.Acute (<12 weeks) or atypical debut, or episodes of any of the following:
- •a.Symptoms of encephalopathy:
- •?psychotic symptoms, including hallucinations, delusions, paranoia, disorganized speech, disorganized behavior
- •?agitation, confusion
- •?sudden change in personality as perceived by the social environment
- •?drowsiness
- •?loss of functions in daily life
- •?cognitive problems (memory, speech, learning)
- •?emotional dysregulation
- •b.Focal neurological symptoms, e.g.
- •?ataxia, dystonia, myoclonus, sensory losses, paresthesia
- •c.Psychomotor anomaly,
- •?e.g. retardation, catatonic symptoms, parkinsonism
- •d.Loss of drive (sleep, appetite, libido, motivation)
- •e.Obsessions, compulsions (OCD/OCB),
- •f.Hypo- or hypervigilance (for e.g sounds, emotions, other peoples´ or own behavior)
- •g.Sleeping disorders,
- •12.At least one of the following criteria:
- •a.Prodromal phase with infection or symptoms of infection (fever, malaise, etc)
- •b.Clinical improvement of psychiatric symptoms after treatment with anti-inflammatory medications other than antibody therapy (such as steroids, NSAIDs IVIG, plasmaphereses), or antibiotics
- •c.Radiological evidence of neuroinflammation (MR)
- •d.EEG pathology or witnessed epileptic seizure
- •e.Biochemical evidence of inflammation, autoimmunity or blood-brain barrier dysfunction in blood or CSF samples, such
排除标准
- •13.Concomitant malignancies or previous malignancies within the last five years
- •14.Cannot comply with vaccination recommendations
- •15.History of severe allergic or anaphylactic reactions in conjunction with prior treatment with monoclonal antibodies
- •16.Prior antibody therapy including Rituximab (MabThera®/Rituxan®)
- •17.Patient has been treated with clozapine (which may have immunosuppressant effect), systemic corticosteroids or IVIG within 60 days prior to screening visit
- •18.Prior treatment with immunosuppressant medications (not including systemic corticosteroids and IVIG) for other medical condition
- •19.History of or positive screening for HIV, Tuberculosis, Hepatitis B and/or Hepatitis C (ever)
- •20.Heart disease such as previous heart attack, arrhythmia or heart failure, coronary insufficiency
- •21.Current drug, alcohol, or chemical abuse
- •22.Pregnancy at any time during the study
- •23.Known significant bacterial/viral/fungal infections at infusion date
- •24.Diagnosis of well-established neuroinflammatory disease such as MS (ICD codes G00–G09, G35–G37) or SLE (M32)
- •25.Tested positive for autoantibodies in serum or CSF associated to known and treatable neuroinflammatory disease (such as neuroborreliosis, treatable autoimmune encephalitis). Patients having completed recommended treatment without significant improvement may still be included in this study.
- •26.History of any illness that in the opinion of the investigator may jeopardize the ability of the patient to participate in the study.
- •27.Patient is enrolled in another medical trial.
研究者
相似试验
进行中（未招募）
1 期
adalimumab intralesional in intestinal strictures of Crohn's disease patientsCrohn diseaseMedDRA version: 16.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2012-001723-12-ESFundació Clínic per a la Recerca Biomèdica102
已完成
1 期
Blood stage challenge study to assess Tafenoquine prophlyaxis against Plasmodium falciparum in healthy volunteers.Malaria infectionACTRN1261700010237060 Degrees Pharmaceuticals Australia (60P) Pty Ltd16
进行中（未招募）
1 期
To study the antidepressive effects of the endogen compound NPY in patients with depression.Major depressive disorderMedDRA version: 18.0Level: LLTClassification code 10025454Term: Major depressive disorder, recurrent episodeSystem Organ Class: 100000004873EUCTR2014-000129-19-SEKarolinska University Hospital, Huddinge70
进行中（未招募）
1 期
Investigating otilimab in patients with severe coronavirus related lung disease.Severe pulmonary COVID-19 related diseaseMedDRA version: 23.0Level: LLTClassification code 10053983Term: Corona virus infectionSystem Organ Class: 100000004862EUCTR2020-001759-42-BEGlaxoSmithKline Research & Development Limited1,150
进行中（未招募）
1 期
A study to determine the added value of vitamin D3 to treatment with subcutaneous immunotherapy in patients with birch pollen allergysubcutaneous immunotherapy in allergic rhinitis (AR) patients with allergies to birchpollenEUCTR2018-001339-33-NLAcademisch medisch centrum Amsterdam40